Tibet Cheezheng Tibetan Medicine Co Ltd - Asset Resilience Ratio
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) has an Asset Resilience Ratio of 37.31% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Tibet Cheezheng Tibetan Medicine Co Ltd's Asset Resilience Ratio has changed over time. Check 002287 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tibet Cheezheng Tibetan Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tibet Cheezheng Tibetan Medicine Co Ltd (002287) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.48 Billion | 37.31% |
| Total Liquid Assets | CN¥2.48 Billion | 37.31% |
Asset Resilience Insights
- Very High Liquidity: Tibet Cheezheng Tibetan Medicine Co Ltd maintains exceptional liquid asset reserves at 37.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tibet Cheezheng Tibetan Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tibet Cheezheng Tibetan Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Tibet Cheezheng Tibetan Medicine Co Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Tibet Cheezheng Tibetan Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.18% | CN¥2.57 Billion ≈ $376.34 Million |
CN¥6.92 Billion ≈ $1.01 Billion |
-4.16pp |
| 2024-12-31 | 41.34% | CN¥2.81 Billion ≈ $410.80 Million |
CN¥6.79 Billion ≈ $993.65 Million |
+10.18pp |
| 2023-12-31 | 31.17% | CN¥1.96 Billion ≈ $287.26 Million |
CN¥6.30 Billion ≈ $921.67 Million |
+5.02pp |
| 2022-12-31 | 26.15% | CN¥1.54 Billion ≈ $225.25 Million |
CN¥5.89 Billion ≈ $861.40 Million |
+4.88pp |
| 2021-12-31 | 21.26% | CN¥1.18 Billion ≈ $173.25 Million |
CN¥5.57 Billion ≈ $814.74 Million |
+20.18pp |
| 2019-12-31 | 1.08% | CN¥32.28 Million ≈ $4.72 Million |
CN¥2.98 Billion ≈ $436.67 Million |
-17.94pp |
| 2018-12-31 | 19.02% | CN¥440.00 Million ≈ $64.39 Million |
CN¥2.31 Billion ≈ $338.43 Million |
+0.69pp |
| 2017-12-31 | 18.33% | CN¥421.00 Million ≈ $61.61 Million |
CN¥2.30 Billion ≈ $336.06 Million |
+8.70pp |
| 2016-12-31 | 9.64% | CN¥200.00 Million ≈ $29.27 Million |
CN¥2.08 Billion ≈ $303.74 Million |
-3.41pp |
| 2015-12-31 | 13.04% | CN¥270.00 Million ≈ $39.51 Million |
CN¥2.07 Billion ≈ $302.93 Million |
-5.76pp |
| 2014-12-31 | 18.81% | CN¥337.00 Million ≈ $49.31 Million |
CN¥1.79 Billion ≈ $262.21 Million |
-- |
About Tibet Cheezheng Tibetan Medicine Co Ltd
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral tibetan medicines, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculo… Read more